148 related articles for article (PubMed ID: 8453356)
1. Interleukin-2 in autologous bone marrow transplantation.
Charak BS
Natl Med J India; 1993; 6(1):19-22. PubMed ID: 8453356
[TBL] [Abstract][Full Text] [Related]
2. Generation and characterization of IL-2-activated bone marrow cells as a potent graft vs tumor effector in transplantation.
Agah R; Malloy B; Kerner M; Mazumder A
J Immunol; 1989 Nov; 143(9):3093-9. PubMed ID: 2809219
[TBL] [Abstract][Full Text] [Related]
3. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
[TBL] [Abstract][Full Text] [Related]
4. Experimental evidence of interleukin-2 activity in bone marrow transplantation.
Mazumder A
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S37-42. PubMed ID: 9457392
[TBL] [Abstract][Full Text] [Related]
5. In vitro LAK (lymphokine activated killer) activity following autologous peripheral blood stem cell is significantly greater than that following autologous bone marrow and allogeneic bone marrow transplantation.
Fegan C; Thomas H; Bailey-Wood R; Coleman S; Phillips S; Hoy T; Whittaker JA
Bone Marrow Transplant; 1995 Aug; 16(2):277-81. PubMed ID: 7581148
[TBL] [Abstract][Full Text] [Related]
6. Effects of ultraviolet B irradiation on human natural killer cell and lymphokine activated killer cell activity: therapeutic potential in bone marrow transplantation and tumor immunotherapy.
Yaron I; Zakheim AR; Oluwole SF; Hardy MA
Transplant Proc; 1995 Feb; 27(1):1379. PubMed ID: 7878918
[No Abstract] [Full Text] [Related]
7. Antileukemic effect of interleukin-2-transduced murine bone marrow after autologous transplantation.
Tam YK; Klingemann HG
Biol Blood Marrow Transplant; 1999; 5(4):231-42. PubMed ID: 10465103
[TBL] [Abstract][Full Text] [Related]
8. IL-2 treatment after autologous bone marrow transplantation in poor prognosis Hodgkin's disease: defective IL-2-induced LAK activity?
Tiberghien P; Racadot E; Fest T; Lioure B; Pariset J; Delain M; Voillat L; Flesch M; Amsallem D; Plouvier E
Bone Marrow Transplant; 1991; 7 Suppl 2():145. PubMed ID: 1878686
[No Abstract] [Full Text] [Related]
9. Interleukin-2 and syngeneic bone marrow transplantation in a murine fibrosarcoma model.
Ho SP; Stebler B; Ershler WB
Lymphokine Cytokine Res; 1991 Apr; 10(1-2):101-4. PubMed ID: 1873353
[TBL] [Abstract][Full Text] [Related]
10. Activity of interleukin-2 in non-Hodgkin's lymphoma following transplantation of interleukin-2-activated autologous bone marrow or stem cells.
van Besien K; Margolin K; Champlin R; Forman S
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S54-8. PubMed ID: 9457395
[TBL] [Abstract][Full Text] [Related]
11. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.
Miller JS; Tessmer-Tuck J; Pierson BA; Weisdorf D; McGlave P; Blazar BR; Katsanis E; Verfaillie C; Lebkowski J; Radford J; Burns LJ
Biol Blood Marrow Transplant; 1997 Apr; 3(1):34-44. PubMed ID: 9209739
[TBL] [Abstract][Full Text] [Related]
12. Phenotypic and functional characterization of peripheral blood and bone marrow natural killer cells prior to autologous transplantation.
Arbour S; Toupin S; Bélanger R; Gyger M; Hallé JP; Perreault C; Roy DC
Bone Marrow Transplant; 1996 Mar; 17(3):315-22. PubMed ID: 8704680
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-2 in bone marrow transplantation.
Verma UN; Charak BS; Rajagopal C; Mazumder A
Cancer Treat Res; 1995; 76():315-36. PubMed ID: 7577342
[No Abstract] [Full Text] [Related]
14. A novel approach to immunomodulation of frozen human bone marrow with interleukin-2 for clinical application.
Charak BS; Areman EM; Dickerson SA; Choudhary GD; Sacher R; Kotula PL; Brown EG; Mazumdar A
Bone Marrow Transplant; 1993 Feb; 11(2):147-54. PubMed ID: 8435664
[TBL] [Abstract][Full Text] [Related]
15. High-dose systemic interleukin-2 therapy in stage IV neuroblastoma for one year after autologous bone marrow transplantation: pilot study.
Pardo N; Martí F; Fraga G; Illa J; Badell I; Peiró M; Bertran E; García J; Rueda F; Cubells J
Med Pediatr Oncol; 1996 Dec; 27(6):534-9. PubMed ID: 8888813
[TBL] [Abstract][Full Text] [Related]
16. Antileukemic effect of interleukin-2-transduced murine bone marrow after autologous transplantation.
Tam YK; Klingemann HG
Biol Blood Marrow Transplant; 1999; 5(3):144-54. PubMed ID: 10392960
[TBL] [Abstract][Full Text] [Related]
17. Acute myeloblastic leukaemia: graft-versus-host and graft-versus-leukaemia responses to autologous IL-2 activated lymphocytes in rapid and slow disease.
Boughton BJ; Simpson AW
Cytokines Cell Mol Ther; 1999 Mar; 5(1):1-6. PubMed ID: 10390074
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy with interleukin-2 after autologous bone marrow transplantation for hematologic malignancies.
Benyunes MC; Thompson JA; York A; Buckner CD; Fefer A
Prog Clin Biol Res; 1994; 389():229-38. PubMed ID: 7700905
[No Abstract] [Full Text] [Related]
19. Natural killer cells in peripheral blood after autologous bone marrow transplantation: a combined phenotypic and functional study.
Jorgensen H; Hokland P; Jensen T; Basse P; Hokland M
Nat Immun; 1995; 14(3):164-72. PubMed ID: 8832900
[TBL] [Abstract][Full Text] [Related]
20. Suppression of alloreactivity with gamma delta T-cells: relevance to increased gamma delta T-cells following bone marrow transplantation.
Nagai M; Azuma E; Qi J; Kumamoto T; Hiratake S; Hirayama M; Umemoto M; Komada Y; Sakurai M
Biomed Pharmacother; 1998; 52(3):137-42. PubMed ID: 9755807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
